Global Pharmaceutical Continuous Manufacturing Market
Pharmaceutical continuous manufacturing is an advanced approach used to formulate pharmaceutical products on a single, uninterrupted production line. It aids in monitoring the production procedures, improving the quality and consistency of medicines, reducing the medicine formulation duration, and eliminating the risk of human errors. Additionally, it offers greater control to manufacturers as compared to batch processing, makes tracking and tracing more flexible, and eliminates physical intervention. As a result, this approach is widely used by pharmaceutical companies to develop active pharmaceutical ingredients (API) and medicines.
How Big Is the Pharmaceutical Continuous Manufacturing Market?
The global pharmaceutical continuous manufacturing market reached a value of US$ 1.2 Billion in 2022. It is projected to reach a value of US$ 2.3 Billion by 2028, exhibiting a CAGR of 11.6% during 2023-2028.
Pharmaceutical Continuous Manufacturing Market Trends and Drivers:
There is a rise in the prevalence of several chronic ailments, such as hypertension, asthma, cardiovascular disease, stroke, and cancer. This is catalyzing the need for novel drugs and therapies worldwide. Along with this, the driving demand for effective medicine production systems to formulate numerous effective biologics at minimal cost is positively influencing the growth of the market. It can also be attributed to the rising drug shortages and the outbreak of viral infections across the globe. Furthermore, the integration of artificial intelligence (AI) solutions and rapid automation in the pharmaceutical manufacturing methodology to accelerate the production capacity is strengthening the growth of the market. Moreover, the easy availability of Food and Drug Administration (FDA) approved medicines across offline and online distribution channels is, in turn, creating a positive market outlook.
What Is Included in Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Therapeutics Type:
- Large Molecules
- Small Molecules
Breakup by Formulation:
- Solid Formulation
- Liquid and Semi-solid Formulation
Breakup by Application:
- Final Drug Product Manufacturing
- API Manufacturing
Breakup by End User:
- Pharmaceutical Companies
- Contract Manufacturing Organizations
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Who Are the Key Players Operating In The Industry?
Top Key Players covered in this report are: Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.
